Ovation.io Announces US$1.5 Million in Funding to Help Tell the Story Behind the Science

Today Ovation.io, the parent company behind Ovation Service Lab and Ovation Research, announced a US$1.5 million investment led by StageDotO and including existing investors. The funding will help Ovation.io to build on the success of both its products in supporting the work of the most forward-thinking biomedical labs, companies, and consortia in both clinical and pre-clinical scientific research. The recent announcement highlights the work of one Ovation Research customer, the iGeneTrain consortium based at the University of Pennsylvania, which relies on global collaboration around shared data and analyses in an effort to improve the understanding of organ transplant outcomes. Get in touch with Ovation.io to learn more about the problems that it solves every day for scientific researchers throughout the world.

[Dan Featherstone](/content/author/dfeatherstone/ "Dan Featherstone"/index.html)

May 24, 2017

Ovation Reaches 10,000 GLP-1 Clinicogenomic Patient Milestone, Now Available for Licensing

PrecisionLife and Ovation ink collaboration agreement to launch GLP-1 stratification LDT and consumer GLP-1 DNA test in H2 2026

PrecisionLife and Ovation identify first potential genetic biomarkers to quantitatively predict GLP-1 efficacy response

Ovation and DNAnexus Present at the 2nd Precision Medicine in IBD Summit

Learn about the transformative power of leveraging high-value multiomics data alongside an advanced.

Linking Genomic and Phenotypic Data to Better Understand the Patient Journey

In partnership with Datavant, we explore how researchers can overcome the challenges posed by..

We looking forward to speaking with you!